← boardnext 2026-07-31next 2027-11-30next 2027-12-23next 2028-01-28next 2028-04-01next 2028-06next 2028-10-25next 2028-12-15
JAZZ
Jazz Pharmaceuticalsdistress 0/10 · well-funded / low risk$250.72+0%today-1% from 52w high
Lead: HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma
Revenue
$1069M
Liquidity
$1844M
Runway
—
Shares 1y
+3%
Price & events
+46.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
+3.5%
1W
+8.9%
1M
+25.4%
3M
+48.6%
6M
+113.7%
1Y
+131.2%
2Y
+44.2%
5Y
+56.3%
All
Overview
- Market Cap
- $15.73B
- Enterprise Value
- $18.21B
- Volume
- 16.29K
- 52 Week Range
- $106 – $254
- Total Shares
- 62.74M
- Float Shares
- 60.80M
- Short %
- 5.74%
- % Held by Insiders
- 3.08%
- % Held by Institutions
- 107.76%
- RVOL
- 0.02x
- Beta
- 0.32
Pipeline stages · 8 programs
Zanidatamab, Cisplatin, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
JZP898, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Xywav
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Lurbinectedin, Durvalumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
JZP815
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dordaviprone (ONC201)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
JZP3507
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ONC206, ONC206: Dose 1, ONC206: Dose 2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 13 trials · 13 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-31 Estimated 50% readout ~2026-10-14 | Phase 3 | Zanidatamab, Tislelizumab, Trastuzumab | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | — | active not recruiting |
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 2 | Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | — | recruiting |
| 2027-11-30 Estimated 50% readout ~2027-12-30 | Phase 1 | JZP898, Pembrolizumab | Advanced Solid Tumor, Metastatic Solid Tumor | — | recruiting |
| 2027-12-23 Estimated 50% readout ~2028-03-07 | Phase 3 | Xywav | Narcolepsy, Idiopathic Hypersomnia | — | not yet recruiting |
| 2028-01-01 Estimated 50% readout ~2028-02-15 | Phase 2 | Zanidatamab, Paclitaxel, Docetaxel | HER2-positive Breast Cancer, Breast Cancer | — | recruiting |
Show all 13 trials · 8 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-01-28 Estimated 50% readout ~2028-03-13 | Phase 1/2 | Lurbinectedin | Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma | — | recruiting |
| 2028-01-31 Estimated 50% readout ~2028-03-16 | Phase 2 | Lurbinectedin, Durvalumab | Extensive-stage Small-cell Lung Cancer | — | not yet recruiting |
| 2028-04-01 Estimated 50% readout ~2028-05-01 | Phase 1 | JZP815 | Advanced Cancer, Metastatic Cancer, Solid Tumor | — | recruiting |
| 2028-04-28 Estimated 50% readout ~2028-07-12 | Phase 3 | Zanidatamab, Trastuzumab, Eribulin | Metastatic HER2-positive Breast Cancer | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | Dordaviprone (ONC201)priority review | H3 K27M, Glioma | — | recruiting |
| 2028-10-25 Estimated 50% readout ~2028-12-09 | Phase 2 | JZP3507 | Meningioma | — | not yet recruiting |
| 2028-12-01 Estimated 50% readout ~2029-02-14 | Phase 3 | Zanidatamab, Cisplatin, Gemcitabine | Biliary Tract Cancer | — | recruiting |
| 2028-12-15 Estimated 50% readout ~2029-01-29 | Phase 2 | ONC206, ONC206: Dose 1, ONC206: Dose 2 | Advanced Pheochromocytoma and Paraganglioma, PCPG | — | recruiting |
Catalyst news & presentations · 9
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 3Ziihera (zanidatamab-hrii) · Additional OS interim analysis for Ziihera plus chemotherapy armSEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)Ziihera (zanidatamab-hrii) · Submit supplemental BLA for first-line treatmentSEC 8-K
- first quarter of 2026conferencedata presentationsecondaryZiihera (zanidatamab-hrii) · Present top-line results at major medical meetingSEC 8-K
- 2025-10-21partnershipLumryz · Jazz grants Avadel license to patents for Lumryz in Narcolepsy (immediate) and Non-Narcolepsy (March 2028); Avadel pays royalties; Jazz pays $90M.SEC 8-K
- August 18, 2025PDUFAPDUFAdordaviprone · PDUFA action date for dordaviprone NDA under Priority ReviewSEC 8-K
- 2025-03-04partnershipJazz Pharmaceuticals enters into definitive agreement to acquire Chimerix.SEC 8-K
- Wednesday, December 11, 2024 at 4:30 p.m. ETconferencedata presentationsecondaryZiihera · Investor webcast to discuss clinical data, patient need and commercialization strategySEC 8-K
- 2024-08-27fda agreementLumryz · Court granted permanent injunction preventing Avadel from seeking FDA approval for new Lumryz indications and enjoining patent infringement.SEC 8-K
Approved drugs (9)
- ZIIHERAZANIDATAMAB-HRII2024 · Prescription
- RYLAZEASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN2021 · Prescription
- XYWAVCALCIUM OXYBATE2020 · Prescription
- ZEPZELCALURBINECTEDIN2020 · Prescription
- DEFITELIODEFIBROTIDE SODIUM2016 · Prescription
- LUVOXFLUVOXAMINE MALEATE2008 · Prescription
- LUVOX CRFLUVOXAMINE MALEATE2008 · Discontinued
- FAZACLO ODTCLOZAPINE2004 · Discontinued
- XYREMSODIUM OXYBATE2002 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $263 (+5% upside) · 20 analysts
- 2026-07-20NeedhamBuy
- 2026-07-17Canaccord GenuityBuy
- 2026-07-14BarclaysOverweight
- 2026-07-14Wells FargoOverweight
- 2026-07-09Deutsche BankBuy
- 2026-07-07Truist SecuritiesBuy
Competitors — HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma
- ZYMEZymeworks Inc.$1.7B · D1
Recent news
- 2026-07-21Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com - Investing.com Nigeria
- 2026-07-21Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com - Investing.com South Africa
- 2026-07-21Jazz Pharmaceuticals stock hits all-time high at 250.85 USD - Investing.com
- 2026-07-21Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com - Investing.com Canada
- 2026-07-20Jazz Pharmaceuticals sets Aug. 3 webcast after market close - Stock Titan
- 2026-07-20Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 - PR Newswire UK
- 2026-07-19Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative? - simplywall.st
- 2026-07-19Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative? - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.